EarningsQ2 2026 Earnings Report
DE:7BG Q2 2026 EPS Results
Actual EPS-€1.42
Consensus EPS―
Beat/Miss―
One Year Ago EPS-€8.28
DE:7BG Q2 2026 Revenue Results
Actual Revenue€761.32K
Expected Revenue―
Beat/Miss―
YoY Revenue Growth+72.76%
Earnings Announcement Details
QuarterQ2 2026
Date08/27/2026
TimeBefore Open
Conference CallThursday, August 27, 2026
DE:7BG Upcoming Earnings
Oncoinvent ASA's next earnings date is estimated for October 28, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and clinical momentum: notably accelerated Phase II recruitment, site expansion, positive early clinical signals (low recurrence in Phase I), strengthened IP and scientific visibility, and disciplined near-term financial management. Key risks were also highlighted, including the need for additional funding beyond 2027 to execute Phase III, manufacturing scaling and redundancy needs, increased payroll/regulatory costs, and absence of announced partnerships. On balance, the positives (clear trial progress, regulatory designation, controlled cash burn, and Phase III preparation) outweigh the listed challenges, which are acknowledged and being actively addressed.Company Guidance
Accelerated Phase II Recruitment
55 patients recruited into the randomized Phase II ovarian cancer trial (crossed the halfway mark). Recruitment accelerated with the two best quarters in Q1 and Q2 2026 and by May 2026 they had recruited more patients than during all of 2025.
Expansion of Trial Sites
Active sites increased from 6 last year to 10 today (added 4 sites in the first two quarters: 1 in Italy, 1 in the U.K., 2 in Spain) — a ~66.7% increase in active sites; 2–3 additional hospitals planned in the next 2 quarters.
Strong Early Clinical Signals and Regulatory Pathway
Phase I ovarian data showed meaningful results (only 1 of 10 patients recurred after 2 years, i.e., 10% recurrence). Company holds FDA Fast Track designation in ovarian cancer and is preparing for Phase III with regulatory engagement.
Scientific Visibility and IP Strengthening
Phase I data presented at ESGO; dosimetry data published in the Journal of Nuclear Medicine; abstracts accepted at ESMO and EANM. IP position strengthened in China with new patents.
Financial Discipline and Cash Position
Cash and equivalents of NOK 109 million (plus NOK 2 million restricted) as of June 30. H1 operating cash burn was NOK 69 million — in line with or slightly below budget and described as proportional to increased recruitment.
Manufacturing and Phase III Readiness
Own pilot plant provides manufacturing control and derisks supply; company is securing raw materials, planning tech transfer and automation, and pursuing a CDMO for redundancy to be Phase III and commercial ready.
Leadership and Organizational Progress
Appointed a new CFO (Ramzi Amri) and promoted experienced internal talent (Sara Westrøm as Scientific Director), supporting clinical, regulatory and business development activities.
DE:7BG Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed